Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced a live conference call and webcast on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a corporate update. Investors can access the call by dialing (833) 636-1323 domestically or (412) 902-4279 internationally, or via its website. Syros is focused on developing innovative medicines that control gene expression, with a robust pipeline including tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, among other candidates.

Positive

• Robust clinical pipeline featuring innovative treatments like tamibarotene and SY-2101.
• Focus on diseases often unaddressed by other genomics-based approaches, potentially expanding market opportunities.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 9, 2022 to report its second quarter 2022 financial results and provide a corporate update.

To access the live conference call, please dial (833) 636-1323 (domestic) or (412) 902-4279 (international) and refer to the “Syros Pharmaceuticals Conference Call.” A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005265/en/

Media:

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com

Investors:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When is the earnings call for Syros Pharmaceuticals?

The earnings call for Syros Pharmaceuticals is scheduled for August 9, 2022, at 8:30 a.m. ET.

What will be discussed in Syros Pharmaceuticals' earnings call?

Syros Pharmaceuticals will report its second quarter 2022 financial results and provide a corporate update during the earnings call.

How can I access the Syros Pharmaceuticals earnings call?

You can access the Syros Pharmaceuticals earnings call by dialing (833) 636-1323 domestically or (412) 902-4279 internationally, or through their website.

What is Syros Pharmaceuticals known for?

Syros Pharmaceuticals is known for developing medicines that control gene expression and has a focus on oncology and monogenic diseases.